Biocon Biologics has successfully simplified its capital structure, leading to an upgrade in its ratings by S&P Global. By ...

Biocon recently unveiled three new biosimilar oncology assets to its R&D pipeline —trastuzumab/hyaluronidase (Herceptin ...

Biocon Limited board approves QIP at ₹387.74 per share, with issue opening on 12 January 2026 and new oncology biosimilars announced.

BRIDGEWATER, N.J. and BENGALURU, India, Oct. 16, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: ...

HYDERABAD, Jan 30 (Reuters) - Indian biopharma company Biocon (BION.NS), opens new tab reported third-quarter revenue on Thursday that fell about 3% when compared with the year-earlier period, which ...

BRIDGEWATER, N.J. and BENGALURU, India, April 10, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Food and ...

Biotech firm Biocon on Thursday said it has raised Rs 4,150 crore through a Qualified Institutions Placement (QIP) process.

Pharma stocks rise as Cipla faces supply issues, Zydus gains FDA approval, and Biocon secures funding through a QIP.

On Wednesday, Biocon stock slipped 0.55 per cent to settle at Rs 364.55 apiece on the BSE.

Biocon’s insulin copycat aspart hit another roadblock as the FDA issued a complete response letter (CRL), saying the Malaysia production facility still must undergo a pre-approval inspection to ...

HYDERABAD, Aug 8 (Reuters) - Biopharmaceutical company Biocon Ltd (BION.NS), opens new tab reported a more than six-fold rise in first-quarter profit on Thursday, boosted by a one-time gain from the ...

Biocon said the proceeds would be primarily used to meet the cash consideration payable to Mylan Inc, now Viatris, for the acquisition of its shareholding in Biocon Biologics Ltd.